XORTX Therapeutics Inc.
XRTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.03 | -0.01 | 0.62 |
| FCF Yield | -114.31% | -152.06% | -60.83% | -18.83% |
| EV / EBITDA | -0.22 | -0.45 | -0.61 | -5.14 |
| Quality | ||||
| ROIC | -106.46% | -118.75% | -90.60% | -13.56% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.11 | 3.05 | 1.26 | 3.67 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 43.92% | 25.20% | -85.17% | -544.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.66 | 1.67 | 1.49 | 14.60 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -651.93 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.57 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 133.76 | -8,504.99 | -10,576.87 |